期刊文献+

两种方案治疗慢性乙型肝炎疗效对比及成本-效果分析

Contrast of Therapeutic Effects Between Two Schemes in Treating the CHB and the Cost-Effectiveness Analysis
下载PDF
导出
摘要 目的:寻找一种经济、有效、安全的治疗慢性乙型肝炎(CHB)方案。方法:将符合慢性乙型肝炎标准80例分成两组。分别以A方案(n=40):注射用母牛分枝杆菌菌苗(微卡)+乙肝疫苗+潘生丁;B方案(n=40):注射用重组人干扰素α_(1b)(赛诺金)治疗。6个月为1个疗程。观察乙肝病毒的核糖核酸(HBV-DNA)、乙型肝炎e抗原(HBeAg)临床转阴率并做成本-效果分析。结果:两组有效率分别为87.5%和92.5%,两组比较差异无统计学意义(P>0.05);两组成本分别为3270.84元;10873.20元.A、B方案成本-效果比分别为37.38,117.55。结论:A方案为最佳治疗CHB经济、有效、安全的方案。 Objective: To seek an economical effective and safe scheme for the treatment of CHB( chronic hepatitis B), Method: 80 cases of CHB were divided into two groups: Group A (n =40) : treated with mycobacterium vaccine for injection(VACCAE) , HBB and dipyridamole In Groups B (n = 40) the medicine was recombinant human interferon α1b for injection( SINOGEN)with one course of 6 months. The HBV-DNA, HBeAg and their clinical improvement rates were observed and the cost-effectiveness was analyzed, Result: The effective rates of 2 groups were 87.5% and 92, 5% respectively, No statistical difference( P 〉 0. 05 )was found in the 2 groups, The costs of the 2 groups were 3270、 84 yuan and 10 873, 20 yuan respectively, and the cost-effectiveness rates were 37, 38 and 117, 55 respectively. Conclusion: Scheme A is an effective, safe and economical scheme in the treatment of CHB.
出处 《药物流行病学杂志》 CAS 2008年第1期54-56,共3页 Chinese Journal of Pharmacoepidemiology
基金 韶关市医药卫生科研资助项目(Y04067)
关键词 母牛分枝杆菌菌苗 重组人干扰素 慢性乙型肝炎 乙肝病毒核糖核酸 乙型肝炎E抗原 成本-效果分析 Mycobacterum vaccine Recombinant human interferon α1b Chronic hepatitis B HBV-DNA HBeAg Cost-effectiveness analysis
  • 相关文献

参考文献5

二级参考文献13

共引文献14146

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部